Tag Archives: NASDAQ:AGRX

Maxim Group Sticks to Its Buy Rating for Agile Therapeutics (AGRX)

Maxim Group analyst Caroline Palomeque maintained a Buy rating on Agile Therapeutics (AGRX – Research Report) today and set a price target of $3. The company’s shares opened today at $1. Palomeque commented: “Agile Therapeutics announced topline results from its

Analysts Are Bullish on These Healthcare Stocks: Agile Therapeutics (AGRX), NovaBay Pharma (NBY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agile Therapeutics (AGRX – Research Report), NovaBay Pharma (NBY – Research Report) and Avenue Therapeutics Inc (ATXI – Research Report) with bullish

Agile Therapeutics Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Agile Therapeutics (NASDAQ: AGRX) today and set a price target of $8. The company’s shares closed yesterday at $2.83. Livnat said: “FDA Exchange NASDAQ Value (M) $76.9 Market Cap (M)

H.C. Wainwright Remains a Buy on Agile Therapeutics

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Agile Therapeutics (NASDAQ: AGRX) today and set a price target of $8. The company’s shares closed yesterday at $3.64. According to TipRanks.com, Livnat is a 1-star analyst with an average

Agile Therapeutics was Downgraded to a Hold Rating at William Blair

Agile Therapeutics (NASDAQ: AGRX) received a Hold rating from William Blair analyst Tim Lugo today. The company’s shares opened today at $2.57, close to its 52-week low of $1.82. According to TipRanks.com, Lugo is a 4-star analyst with an average

Agile Therapeutics Received its Third Buy in a Row

After H.C. Wainwright and Cantor Fitzgerald assigned a Buy rating to Agile Therapeutics in the last month, the company received another Buy, this time from Noble Financial. Analyst Caroline Palomeque reiterated a Buy rating on Agile Therapeutics (NASDAQ: AGRX) yesterday.